Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings: 2009-2025

Historic Retained Earnings for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$46.0 million.

  • China Pharma Holdings' Retained Earnings fell 7.47% to -$46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 7.47%. This contributed to the annual value of -$44.0 million for FY2024, which is 12.05% down from last year.
  • China Pharma Holdings' Retained Earnings amounted to -$46.0 million in Q3 2025, which was down 1.45% from -$45.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Retained Earnings ranged from a high of -$29.6 million in Q1 2021 and a low of -$46.0 million during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$41.7 million (2024), whereas its average is -$41.5 million.
  • Data for China Pharma Holdings' Retained Earnings shows a maximum YoY declined of 14.32% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Retained Earnings stood at -$32.2 million in 2021, then decreased by 12.32% to -$36.2 million in 2022, then dropped by 8.50% to -$39.3 million in 2023, then declined by 12.05% to -$44.0 million in 2024, then fell by 7.47% to -$46.0 million in 2025.
  • Its Retained Earnings stands at -$46.0 million for Q3 2025, versus -$45.3 million for Q2 2025 and -$44.8 million for Q1 2025.